Skip to main content
OpenTrials
Completed

NCT Number: NCT00663286

A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Burke Pharmaceutical Research, Hot Springs, Arkansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Presence of inflammatory and non-inflammatory lesions

Exclusion criteria

  • Dermatological conditions of the face other than acne that could interfere with clinical evaluations
  • Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study

Treatment and study plan

IDP-110

Drug

Topical application for 12 weeks

Clindamycin

Drug

Topical application for 12 weeks

Benzoyl peroxide

Drug

Topical application for 12 weeks

Vehicle

Drug

Topical application for 12 weeks

Primary outcomes

  1. Change from baseline in number of lesions

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline in global severity

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

Dow Pharmaceutical Sciences

Industry

Registry information

Important dates

Study start
2006
Primary completion
2007
First posted
Apr 22, 2008
Registry last updated
Apr 22, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.